Jennifer L. Brown

Jennifer L. Brown

Auto-generated profile, based on publicly available information

Jennifer L. Brown

Burke Neurological Institute White Plains New York USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Glia
Verified
Journal Article
Closed access
PDF file
BDBrian David
Brian David
JCJessica J. Curtin
Jessica J. Curtin
JBJennifer L. Brown
Jennifer L. Brown
DCDavid J. C. Coutts
David J. C. Coutts
NBNathan C. Boles
Nathan C. Boles
CHCaitlin E. Hill
Caitlin E. Hill

3 July 2021 in Inhalation Toxicology
Verified
Journal Article
Closed access
JBJennifer L. Brown
Jennifer L. Brown
CLCarey E. Lyons
Carey E. Lyons
CTCarlee Toddes
Carlee Toddes
TMTimothy Monko
Timothy Monko
RTRoman Tyshynsky
Roman Tyshynsky
Tear gases, or chemical demonstration control agents (DCA), were originally created as weapons that could severely disable or kill enemy troops. Though banned in war, these chemicals are still used in domestic policing. Here we review the available scientific literature on tear gas, summarizing findings from animal and environmental studies as well describing data from new human studies. We find a lack of scientific evidence supporting the safety of tear gas, especially regarding its long-term impacts on human health and the environment. Many of the available studies were published decades ago, and do not parse data by variables such as chemical type and exposure time, nor do they account for the diversity of individuals who are exposed to tear gas in real-life situations. Due to the dearth of scientific research and the misinterpretation of some of the available studies, we conclude that a serious reevaluation of chemical DCA safety and more comprehensive exposure follow-up studies are necessary.


1 January 2023 in Cell Transplantation
Verified
Journal Article
Open access
JBJennifer L. Brown
Jennifer L. Brown
JVJoseph P. Voth
Joseph P. Voth
KPKennedy Person
Kennedy Person
WLWalter C. Low
Walter C. Low
Organ transplantation is a highly utilized treatment for many medical conditions, yet the number of patients waiting for organs far exceeds the number available. The challenges and limitations currently associated with organ transplantation and technological advances in gene editing techniques have led scientists to pursue alternate solutions to the donor organ shortage. Growing human organs in animals and harvesting those organs for transplantation into humans is one such solution. These chimeric animals usually have certain genes necessary for a specific organ’s development inhibited at an early developmental stage, followed by the addition of cultured pluripotent human cells to fill that developmental niche. The result is a chimeric animal that contains human organs which are available for transplant into a patient, circumventing some of the limitations currently involved in donor organ transplantation. In this review, we will discuss both the current scientific and legal landscape of human–animal chimera (HAC) research. We present an overview of the technological advances that allow for the creation of HACs, the patents that currently exist on these methods, as well as current public attitude and understanding that can influence HAC research policy. We complement our scientific and public attitude discussion with a regulatory overview of chimera research at both the national and state level, while also contrasting current U.S. legislation with regulations in other countries. Overall, we provide a comprehensive analysis of the legal and scientific barriers to conducting research on HACs for the generation of transplantable human organs, as well as provide recommendations for the future.

14 December 2022 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
JBJennifer L. Brown
Jennifer L. Brown
DHDamyan W. Hart
Damyan W. Hart
GBGabriel E. Boyle
Gabriel E. Boyle
TBTaylor G. Brown
Taylor G. Brown
MLMichael LaCroix
Michael LaCroix
SLSylvain E. Lesné
Sylvain E. Lesné
Antisense oligonucleotide (ASO) therapy for neurological disease has been successful in clinical settings and its potential has generated hope for Alzheimer’s disease (AD). We previously described that ablating SNCA encoding for α-synuclein (αSyn) in a mouse model of AD was beneficial. Here, we sought to demonstrate whether transient reduction of αSyn expression using ASOSNCA could be therapeutic in a mouse model of AD. The efficacy of the ASOSNCA was measured via immunocytochemistry, RT-qPCR and western blotting. To assess spatial learning and memory, ASOSNCA or PBS-injected APP and non-transgenic (NTG) mice, and separate groups of SNCA-null mice, were tested on the Barnes circular maze. Hippocampal slice electrophysiology and transcriptomic profiling were used to explore synaptic function and differential gene expression between groups. Reduction of SNCA transcripts alleviated cognitive deficits in male transgenic animals, but surprisingly, not in females. To determine the functional cause of this differential effect, we assessed memory function in SNCA-null mice. Learning and memory were intact in male mice but impaired in female animals, revealing that the role of αSyn on cognitive function is sex-specific. Transcriptional analyses identified a differentially expressed gene network centered around EGR1, a central modulator of learning and memory, in the hippocampi of SNCA-null mice. Thus, these novel results demonstrate that the function of αSyn on memory differs between male and female brains.

1 October 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JBJennifer L. Brown
Jennifer L. Brown
KMKatie Murphy
Katie Murphy
TOTimothy D. O’connell
Timothy D. O’connell
SLSylvain E Lesné
Sylvain E Lesné
Free fatty acid receptor 4 (FFAR4/GPR120) is a member of a family of G protein–coupled receptors (GPCRs), which can bind free fatty acids (1). FFAR4 is preferen